BCL2 and acute myeloid leukemia: What had not been demonstrated until now was how AML cells adapt theiranti-apoptotic profile to mitigate the effects of selective BCL-2 antagonism byABT-199 and how that understanding might be exploited to reverse or proactivelyprevent drug resistance.